Officials Warn Of Deaths Linked To Bayer Drug
Health Canada said researchers conducting clinical trials of MabCampath in the U.S. reported that six out of 51 patients died after being treated with the drug after a combination therapy of two other anti-leukemia drugs — fludarabine and rituximab.
All six deceased patients died of infections that were either bacterial, fungal or viral in nature, the agency said.
MabCampath, which is jointly marketed...
To view the full article, register now.